Product Description: Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].
Applications: COVID-19-immunoregulation
Formula: C90H120N20O22S2
References: [1]Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14(1):17515.
CAS Number: 2763602-16-8
Molecular Weight: 1898.17
Compound Purity: 99.89
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : ≥ 100 mg/mL
Target: Interleukin Related;STAT
Deutsch
English
